PMID- 15317403
OWN - NLM
STAT- MEDLINE
DCOM- 20041022
LR  - 20190917
IS  - 0277-0008 (Print)
IS  - 0277-0008 (Linking)
VI  - 24
IP  - 7 Pt 2
DP  - 2004 Jul
TI  - Evolving concepts in the treatment of venous thromboembolism: the role of factor 
      Xa inhibitors.
PG  - 82S-87S
AB  - Anticoagulation is an essential component of the care of patients with venous 
      thromboembolism (VTE). Traditional anticoagulants for the treatment of VTE 
      include unfractionated heparin (UFH), low-molecular-weight heparin (LMWH), and 
      the oral vitamin K antagonist, warfarin. A variety of anticoagulant agents with 
      improved pharmacologic and clinical profiles are emerging and offer benefits over 
      the traditional therapies. One of the most recent advances has been the 
      development of new agents, such as oral direct thrombin inhibitors and factor Xa 
      inhibitors, that have a more selective and targeted effect on the coagulation 
      cascade. Recent clinical trials have evaluated fondaparinux, the first 
      commercially available factor Xa inhibitor, in the treatment of patients with 
      deep vein thrombosis and pulmonary embolism and indicate efficacy and safety as 
      compared with traditional options such as UFH and LMWH. Fondaparinux is a 
      welcomed addition to the available antithrombotic options.
FAU - Nutescu, Edith A
AU  - Nutescu EA
AD  - Department of Pharmacy Practice, College of Pharmacy, University of Illinois at 
      Chicago, Chicago, Illinois 60612, USA. enutescu@uic.edu
FAU - Helgason, Cathy M
AU  - Helgason CM
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Pharmacotherapy
JT  - Pharmacotherapy
JID - 8111305
RN  - 0 (Anticoagulants)
RN  - 0 (Polysaccharides)
RN  - 9000-94-6 (Antithrombin III)
RN  - J177FOW5JL (Fondaparinux)
SB  - IM
MH  - Anticoagulants/adverse effects/*therapeutic use
MH  - Antithrombin III/adverse effects/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Fondaparinux
MH  - Humans
MH  - Polysaccharides/adverse effects/*therapeutic use
MH  - Pulmonary Embolism/drug therapy
MH  - Thromboembolism/*drug therapy
MH  - Venous Thrombosis/*drug therapy
RF  - 31
EDAT- 2004/08/20 05:00
MHDA- 2004/10/23 09:00
CRDT- 2004/08/20 05:00
PHST- 2004/08/20 05:00 [pubmed]
PHST- 2004/10/23 09:00 [medline]
PHST- 2004/08/20 05:00 [entrez]
AID - 10.1592/phco.24.10.82s.36121 [doi]
PST - ppublish
SO  - Pharmacotherapy. 2004 Jul;24(7 Pt 2):82S-87S. doi: 10.1592/phco.24.10.82s.36121.